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Background: Chronic kidney disease (CKD) is an independent risk factor for the development and severity of
coronary artery disease (CHD) and endothelial dysfunction. There is an increase in the circulating angiogenesis
inhibitors endostatin (END), thrombospondin-2 (TSP), angiopoietin-2 (ANG) and the nitric oxide (NO) inhibitor
asymmetric dimethyl arginine (ADMA) in CKD patients. The aim of this study was to evaluate associations of the
serum level of these factors and of the related angiogenesis inhibitor, endoglin (ENG), with burden of coronary
atherosclerosis.
Methods: One hundred twenty-two patients undergoing coronary angiography were recruited from the cardiac
catheterization lab at a single center. The total burden of coronary plaque (mm2) and the presence of coronary
collaterals were quantified using quantitative coronary angiography (QCA). Serum levels of angiogenesis inhibitors
were measured by ELISA (ENG, END, and ANG), Luminex assay (TSP), or HLPC (ADMA), respectively. Associations with
plaque burden and coronary collateral supply were analyzed in multi-variable linear and logistic regression models.
Results: There was no significant association found between levels of circulating ADMA, ENG, END, ANG, or TSP
and coronary plaque burden or collateral formation.
Conclusions: Our findings suggest that associations of circulating END, ENG, TSP, and ANG with cardiovascular
mortality are unlikely to be mediated via direct effects on coronary plaque formation or by inhibition of collateral
formation. Whether associations of these factors with mortality are mediated via local concentrations, myocardial
tissue, or intra-plaque expression of these factors or by an effect on plaque vulnerability merits additional investigation.Background
Despite dramatic therapeutic advances in the recent years,
ischemic heart disease remains the leading cause of death
worldwide [1]. Although traditional, “Framingham” risk
factors are well-established contributors to the pathogen-
esis of coronary disease, and factors beyond hyperlipid-
emia, diabetes, and hypertension appear to play important
roles in the development and progression of atherosclerosis
[2]. Among the myriad non-traditional risk factors impli-
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progression of coronary artery disease [3, 4].
Under normal conditions, the vascular endothelium
plays a key role in maintaining homeostasis, and it func-
tions to promote vasodilation, inhibit luminal and vascu-
lar wall coagulation, and prevent the proliferation of
smooth muscle and foam cells. However, these functions
may be perturbed, particularly when the bioavailability
of nitric oxide (NO) is low, leading to a state favoring
vasoconstriction, thrombosis, vascular smooth muscle
cell proliferation, and the generation of atherosclerotic
plaque [5]. In the setting of such endothelial dysfunction,
imbalances of pro and anti-angiogenic factors contribute
to generation of, hemorrhage-prone, immature capillar-
ies within the vessel wall or within nascent plaques.
Thus, the regulation of angiogenesis appears to be a keyarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Baseline characteristics of the study population
Characteristic (n = 122) Value (N (%))
Demographics
Age (years), mean ± SD 61.35 ± 11.72
Male 82 (67.2)
Black 11 (9.0)
Blood pressure (mmHg), mean ± SD
Systolic blood pressure 127.97 ± 23.01
(n = 118)
Diastolic blood pressure 70.19 ± 13.29
(n = 118)
Medical history
Acute coronary syndrome on presentation 43 (35.2)
Prior myocardial infarction 36 (29.5)
Hypertension 95 (77.9)
Diabetes 46 (37.7)
Chronic dialysis 8 (6.6)
Congestive heart failure 32 (26.2)
Chronic obstructive lung disease 8 (6.6)
Peripheral vascular disease 10 (8.2)
Hyperlipidemia 91 (74.6)









Number of diseased vessels, median [IQR] 1 [0.0, 2.0]
Multi-vessel coronary disease 34 (27.9)
Percent area stenosis (%), median [IQR] 4.96 [3.78, 6.37]
Gensini Score 26.0 [19.5, 39.0]
Labs, mean ± SD
Ejection Fraction (%), median [IQR] 57.0 [45.0, 65.0]
(n = 81)
Hemoglobin, (g/dL) 13.17 ± 1.85
(n = 119)
White blood count (1000/mm3), median [IQR] 7.83 [6.22, 9.04]
(n = 120)
LDL cholesterol (mg/dL) 86.76 ± 36.23
(n = 98)
Serum creatinine (mg/dL), [median IQR] 1.05 [0.84, 1.30]
Estimated glomerular filtration rate, (mL/min) 68.33 ± 30.41
Baseline characteristics of the study population
SD standard deviation, IQR inter-quartile range, Hg mercury, min minute. ACE/
ARB angiotensin converting enzyme inhibitor/angiotensin receptor blocker
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rupture of atherosclerotic plaque [3].
In addition to playing a direct role in endothelial
homeostasis [5, 6], NO is also an important mediator of
angiogenesis. It both induces secondary changes in the
activity and concentration of several angiogenesis inhibi-
tors and is, in turn, modulated by their presence [7–13].
Thus, both NO bioavailability and the concentration of
the related inhibitors of angiogenesis are likely to be
closely linked to the presence of atherosclerosis. Moreover,
we have recently shown that asymmetric dimethyl argin-
ine (ADMA), a key, competitive inhibitor of endothelial
nitric oxide synthase, and related circulating angiogen-
esis inhibitors endostatin (END), thrombospondin-2 (TSP),
and angiopoietin-2 (ANG) are increased in patients with
chronic kidney disease, a patient population at increased
risk for coronary artery disease. We therefore undertook
this study in order to analyze the associations of ADMA
[14] and related circulating angiogenesis inhibitors with
the burden of coronary atherosclerosis as measured using
quantitative coronary angiography (QCA).
Results
Baseline characteristics and angiographic characteristics
There were 122 subjects who met the inclusion criteria
and were enrolled (Table 1). The mean age was 61.4 ±
11.7 years. The majority of subjects (77.9 %) had hyper-
tension, 37.5 % had diabetes, and 34.4 % had stage 3 or
higher chronic kidney disease including eight subjects
on dialysis. Prior myocardial infarction (MI) was com-
monly present in 29.5 % of subjects, while 35.2 % under-
went angiography during an admission for acute coronary
syndrome. The majority of subjects had one vessel disease,
but 34 (27.9 %) had multi-vessel atherosclerosis.
Associations with atherosclerotic burden
Atherosclerotic plaque burden varied widely with a me-
dian atherosclerotic burden occupying 5.0 % (inter-quar-
tile range (IQR) 3.8, 6.4) of the total area of the coronary
circulation. When analyzed according to quartiles of
plaque burden (Table 2), prior MI (P = 0.03) and diabetes
were more prevalent in those with a higher burden of
atherosclerosis (P = 0.01) while hemoglobin was lower
(P = 0.02). Other characteristics aside from alternative
measures of plaque burden (e.g., number of diseased
vessels, Gensini score) were not significantly different in
quartiles of plaque burden. Although there were numer-
ical differences in the level of END, ADMA, TSP, ENG,
and ANG across quartiles of plaque burden (Table 3),
differences were marginal and did not achieve signifi-
cance in unadjusted analyses (P ≥ 0.18 for all compari-
sons). Results were similar in analyses using the Gensini
score in place of the percent area stenosis (data not
shown). There was no evidence of a significant association
Table 2 Baseline characteristics according to plaque burden measured as total percent area stenosis
Variable (N (%)) Q1 Q2 Q3 Q4 P value
2.16–3.78 % 3.86–4.95 % 4.96–6.37 % 6.39–13.2 %
(n = 31) (n = 30) (n = 31) (n = 30)
Demographics
Age (years), mean ± SD 57.03 ± 14.01 62.47 ± 12.47 62.06 ± 9.71 63.97 ± 9.42 0.11
Male 17 (54.8 %) 20 (66.7 %) 23 (74.2 %) 22 (73.3 %) 0.34
Black 3 (9.7 %) 3 (10.0 %) 4 (12.9 %) 1 (3.3 %) 0.61
Blood pressure (mmHg), mean ± SD
Systolic 123.63 ± 23.04 123.96 ± 25.00 136.52 ± 23.97 127.17 ± 18.05 0.10
Diastolic 72.03 ± 13.63 68.11 ± 12.87 71.71 ± 13.87 68.69 ± 12.93 0.57
Medical history
Acute coronary syndrome on presentation 8 (25.8 %) 10 (33.3 %) 15 (48.4 %) 10 (33.3 %) 0.30
Prior myocardial infarction 4 (12.9 %) 10 (33.3 %) 8 (25.8 %) 14 (46.7 %) 0.03
Hypertension 20 (64.5 %) 27 (90.0 %) 25 (80.6 %) 23 (76.7 %) 0.11
Diabetes 6 (19.4 %) 8 (26.7 %) 16 (51.6 %) 16 (53.3 %) 0.01
Chronic dialysis 2 (6.5 %) 2 (6.7 %) 3 (9.7 %) 1 (3.3 %) 0.80
Congestive heart failure 7 (22.6 %) 11 (36.7 %) 8 (25.8 %) 6 (20.0 %) 0.47
Chronic obstructive lung disease 2 (6.5 %) 3 (10.0 %) 2 (6.5 %) 1 (3.3 %) 0.78
Peripheral vascular disease 0 (0.0 %) 2 (6.7 %) 4 (12.9 %) 4 (13.3 %) 0.19
Hyperlipidemia 18 (58.1 %) 24 (80.0 %) 26 (83.9 %) 23 (76.7 %) 0.09
Angiographic findings
Number of diseased vessels, median [QR] 0.0 [0.0, 0.0] 0.0 [0.0, 1.0] 1.0 [1.0, 2.0] 2.0 [2.0, 3.0] <0.001
Multi-vessel coronary disease 0 (0.0 %) 1 (3.3 %) 9 (29.0 %) 24 (80.0 %) <0.001
Gensini score, median [IQR] 19.5 [18.5, 21.0] 21.8 [18.5, 27.0] 29.0 [25.5, 44.5] 45.8 [32.5, 65.0] <0.001
Labs, mean ± SD
Ejection fraction (%), median [IQR] 60.00 [43.75, 63.63] 60.00 [45.00, 65.00] 53.00 [35.00, 65.00] 55.00 [47.00, 60.00] 0.46
Hemoglobin, (g/dL) 13.55 ± 1.57 13.30 ± 1.23 13.54 ± 1.66 12.28 ± 2.48 0.02
White blood count (1000/mm3), median [IQR] 7.72 [6.00, 8.55] 7.22 [6.40, 8.60] 7.95 [5.60, 9.34] 8.26 [6.60, 9.14] 0.14
LDL cholesterol (mg/dL) 101.55 ± 31.19 76.48 ± 30.45 90.04 ± 43.00 81.46 ± 34.67 0.11
Serum creatinine (mg/dL), median [IQR] 1.01 [0.81, 1.30] 1.02 [0.90, 1.22] 1.13 [0.90, 1.41] 1.08 [0.85, 1.24] 0.55
Estimated glomerular filtration rate, (mL/min) 69.01 ± 28.21 70.29 ± 30.70 64.18 ± 33.68 69.96 ± 29.88 0.85
Baseline characteristics of the study population according to percent area stenosis
SD standard deviation, IQR inter-quartile range, Hg mercury, min minute
Table 3 Association of angiogenesis inhibitor concentrations with plaque burden measured as total percent area stenosis
Factor (median [IQR]) Q1 Q2 Q3 Q4 P value
2.16–3.78 % 3.86–4.95 % 4.96–6.37 % 6.39–13.2 %
n = 31 n = 30 n = 31 n = 30
Endostatin (ng/mL) 136.75 [83.51, 198.57] 134.87 [103.91, 191.11] 109.08 [83.17, 184.55] 118.38 [92.03, 150.14] 0.50
ADMA (μmol/L) 0.47 [0.40, 0.54] 0.43 [0.40, 0.51] 0.47 [0.41, 0.50] 0.48 [0.44, 0.56] 0.57
Thrombospondin-2
(pg/mL)
20,900.0 [14,800.0, 26,500.0] 21,000.0 [15,400.0, 33,000.0] 19,100.0 [15,200.0, 26,300.0] 26,000.0 [16,450.0, 33,900.0] 0.45
Endoglin (ng/mL),
mean ± SD
4.43 ± 1.49 4.50 ± 1.08 3.91 ± 0.84 4.47 ± 1.23 0.18
Angiopoietin-2
(ng/mL)
2.08 [1.50, 3.11] 2.75 [1.51, 4.48] 2.45 [1.47, 4.86] 2.23 [1.71, 4.44] 0.79
Quartiles of plaque burden and distribution of mean or median values for endostatin (n = 115), thrombospondin-2 (n = 109), endoglin (n = 116), angiopoietin-2
(n = 108), and ADMA (asymmetric dimethyl arginine, n = 110) concentrations
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lyses adjusted for renal function, acute coronary syndrome
on presentation, age, sex, race, diabetes, hyperlipidemia,
smoking, hypertension, history of heart failure, and per-
ipheral vascular disease (Table 4).
Collateral formation
Collateral vessels were infrequent and were found in
only 20 (16.4 %) subjects. A history of prior MI (P =
0.03) and peripheral vascular disease (P = 0.04) were
more frequent among those with compared to those
without collaterals (Table 5). The number of diseased
vessels was higher, multi-vessel disease was more com-
mon, and indices of plaque burden were significantly
greater in individuals with compared to those without
collaterals. END (126.7 ng/mL: IQR [95.0, 198.6] vs
105.7 ng/mL: IQR [80.4, 131.1]), ENG (4.2 ng/mL: IQR
[3.6, 5.0] vs. 3.5 ng/mL: IQR [3.2, 4.9]). ANG (2.2 ng/
mL: IQR [1.6, 3.8] vs. 2.2 ng/mL: IQR [1.3, 3.2]), ADMA
(0.47 μmol/L: IQR [0.41, 0.52] vs. 0.45 μmol/L: IQR
[0.41, 0.56]), and TSP (21650.0 pg/mL: IQR [15400.0,
29850.0] vs. 19,100 pg/mL: IQR [13400, 31350]) concen-
trations were not significantly different in individuals
without compared to individuals with visible collateral
formation (Fig. 1). Inhibitor concentration was not asso-
ciated with collateral formation in either crude or ad-
justed analyses (Table 6). The results were similar in
sensitivity analyses in which individual vessels rather
than individual patients severed as the unit of analysis
(data not shown).
Discussion
We analyzed atherosclerotic plaque burden and coron-
ary collateral formation using quantitative coronary
angiography and assessed the associations of angiogen-
esis and NO inhibitors with coronary artery disease in
individuals undergoing non-emergent angiography. Al-
though there were small, numerical differences in the
concentrations of several factors, the systemic concen-
trations of ADMA, ENG, END, TSP, or ANG were not
significantly associated with total plaque burden or pres-
ence of collaterals in either crude or adjusted analyses.
Endothelial dysfunction and plaque angiogenesis have
been implicated in the pathogenesis of coronary arteryTable 4 Crude and adjusted associations of plaque burden and ang
Factor (median [IQR]) Unadjusted β (95 % CI)
Endostatin (per 100 ng/mL) −0.16 (−0.04, 0.13)
ADMA (per 0.1 μmol/L) 0.02 (−0.03, 0.08)
Thrombospondin-2 (per 100 pg/mL) 0.02 (0.00, 0.01)
Endoglin (per 1 ng/mL) −0.01 (−0.07, 0.05)
Angiopoietin-2 (per 1 ng/mL) 0.00 (−0.03, 0.02)
Association of inhibitor level with log transformed plaque burdendisease suggesting a key role for NO homeostasis and
angiogenesis inhibitors in the development of human
atherosclerosis [3–6]. In addition to this direct role, NO
bioavailability and inhibitors of angiogenesis may modify
risks associated with the presence of coronary disease by
inhibiting the development of collateral circulations that
reduce myocardial damage and diminish morbidity and
mortality from myocardial ischemia [15–19]. As a result,
there has been a great interest in determining whether
NO or elated inhibitors of angiogenesis are associated
with coronary atherosclerosis.
Although direct measurement of NO in humans is
technically challenging, ADMA, a competitive inhibitor
of NO synthase [14], has been widely studied. ADMA
has been implicated as an independent risk factor for
both all-cause mortality and cardiovascular events
[20, 21], and it has been associated with the presence of
atherosclerosis in some but not all studies [22, 23].
Relatively few studies have examined associations with
coronary atherosclerosis. However, in a recent study of
152 non-diabetic men with obstructive coronary disease
(≥1 vessel with 70 % atherosclerosis), ADMA was corre-
lated with the proportion of the length of the coronary
tree occupied by luminal irregularities, but not with
number of diseased vessels or the Gensini score [24].
Another study of 997 participants found that ADMA
concentration was higher in individuals with ≥50 % cor-
onary stenosis of a coronary artery compared to those
without significant atherosclerosis. However, only un-
adjusted analyses were performed and adjustment for
potential confounders was not performed [25]. Conversely,
another study including 1364 patients with stable angina
reported that ADMA levels were actually significantly
lower in subjects with compared to those without ob-
structive coronary disease, although there were no differ-
ences in the prevalence of three-vessel disease [26]. The
results were similar in a second, large study including
more than 3000 German subjects [27].
The association of collateral formation and ADMA
has been less well studied. However, in a small study
of 61 patients, ADMA concentration was not associ-
ated with collateral formation [28]. In contrast, Kocaman
studied 74 individuals and found that individuals
with collateral development had lower plasma ADMAiogenesis inhibitor concentration
P value Adjusted β (95 % CI) P value
0.28 0.00 (−0.03, 0.036) 0.97
0.39 0.03 (−0.02, 0.09) 0.25
0.37 0.00 (0.00, 0.01) 0.62
0.81 0.01 (−0.05, 0.07) 0.81
0.69 0.01 (–0.02, 0.04) 0.44
Table 5 Baseline characteristics and collateral formation
Variable (N (%)) Collaterals absent Collaterals present P value
(n = 102) (n = 20)
Demographics
Age (years), mean ± SD 61.38 ± 11.86 61.20 ± 11.28 0.95
Male 67 (65.7 %) 15 (75.0 %) 0.42
Black 11 (10.8 %) 0 (0.0 %) 0.12
Blood pressure (mmHg), mean ± SD
Systolic 129.77 ± 23.44 119.15 ± 18.88 0.06
Diastolic 70.40 ± 13.88 69.20 ± 10.13 0.72
Medical History
Acute coronary syndrome on presentation 34 (33.3 %) 9 (45.0 %) 0.32
Prior myocardial infarction 26 (25.5 %) 10 (50.0 %) 0.03
Hypertension 78 (76.5 %) 17 (85.0 %) 0.41
Diabetes 38 (37.3 %) 8 (40.0 %) 0.82
Chronic dialysis 8 (7.8 %) 0 (0.0 %) 0.20
Congestive heart failure 26 (25.5 %) 6 (30.0 %) 0.68
Chronic obstructive lung disease 8 (7.8 %) 0 (0.0 %) 0.20
Peripheral vascular disease 6 (5.9 %) 4 (20.0 %) 0.04
Hyperlipidemia 75 (73.5 %) 16 (80.0 %) 0.54
Angiographic Findings
Number of diseased vessels, median [IQR] 1.0 [0.0, 1.0] 2.0 [1.0, 2.5] <0.001
Multi-vessel coronary disease 20 (19.6 %) 14 (70.0 %) <0.001
Gensini score, median [IQR] 22.25 [19.50, 30.50] 66.50 [56.25, 92.00] <0.001
Percent area stenosis (%), median [IQR] 4.7 [3.6, 6.1] 0.7 [5.0,9.0] <0.001
Labs, mean ± SD
Ejection fraction (%), median [IQR] 57.5 [45.0, 65.0] 55.0 [38.0, 64.0] 0.53
Hemoglobin, (g/dL) 13.25 ± 1.82 12.76 ± 2.01 0.28
White blood count (1000/mm3), median [IQR] 7.66 [6.13, 8.93] 8.17 [6.96, 9.40] 0.22
LDL cholesterol (mg/dL) 88.55 ± 33.58 79.75 ± 45.45 0.34
Serum creatinine (mg/dL), median [IQR] 1.05 [0.83, 1.30] 1.05 [0.89, 1.41] 0.61
Estimated glomerular filtration rate, (mL/min) 68.15 ± 30.43 69.28 ± 31.03 0.88
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eral formation (0.70+/−0.23 μmol/L, P = 0.001) [29].
Our analysis is consistent with the largest prior studies
which similarly failed to demonstrate an association
between ADMA level and coronary atherosclerosis or
collateral formation [27, 26]. Our study extends these
observations by analyzing both aspects of coronary dis-
ease within a single cohort, by adjusting for relevant risk
factors in multi-variable analyses, and by the use of
digital angiography and a fully quantitative method for
assessing atherosclerotic burden thereby permitting more
accurate measurement. Although, as noted above, some
prior studies have identified associations of ADMA with
atherosclerosis [22, 24, 25], the failure to confirm an asso-
ciation of ADMA with a quantitative measure of plaque
burden or with collateral formation suggests that theassociations of ADMA with the risk of all-cause and
cardiovascular mortality [20, 21] are not mediated primar-
ily through the development or extension of atherosclerotic
plaques. Whether ADMA impacts plaque vulnerability is
unknown but further study appears warranted in light of
our data.
We also studied additional angiogenesis inhibitors—-
specifically END, TSP, ANG, and ENG, each of which
has been shown to be induced by or to modulate the re-
sponse to changes in NO bioavailability [7–13, 30]—with
plaque burden and collateral formation. Relatively few
studies have investigated associations of END with coron-
ary atherosclerosis, although myocardial RNA expression
of END was negatively correlated with the Rentrop
score in one study [31]. Similarly, the difference between
coronary sinus and left ventricular END concentration
Fig. 1 Box and whisker plots showing factor concentration according to the presence or absence of collaterals. a Angiopoietin-2. b ADMA.
c Thrombospondin-2. d Endoglin. e Endostatin
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those with collaterals in a study of 72 patients [32]. Finally,
in a study of 39 patients, endostatin levels in pericardial
fluid were inversely correlated with collateral formation
[33]. However, circulating END was not correlated with
collateral formation in an angiographic study of 101 pa-
tients [34] or in a second study of 218 patients [35]. To
our knowledge, the association of circulating END with
plaque burden has not been directly reported, although
coronary sinus END concentration was 1.6-fold higher in
individuals with coronary artery disease compared to
those with atypical chest pain [32].
Elevated levels of TSP [36], ANG [37], and ENG [38]
are associated with increased risks of cardiovascular mor-
tality. An autopsy study of nine patients demonstrated an
increased frequency of ENG expression in coronary le-
sions with intra-plaque hemorrhage—a marker of plaque
vulnerability [39]—but to our knowledge, associations of
ENG with plaque burden or collateral formation have notTable 6 Crude and adjusted associations of angiogenesis inhibitor c
Factor (median [IQR]) Crude odds ratio (95 % CI)
Endostatin (per 100 ng/mL) 0.88 (0.64, 1.21)
ADMA (per 0.1 μmol/L) 1.10 (0.79, 1.54)
Thrombospondin-2 (per 1000 pg/mL) 0.99 (0.96, 1.02)
Endoglin (per 1 ng/mL) 0.82 (0.52, 1.29)
Angiopoietin-2 (per 1 ng/mL) 1.01 (0.87, 1.18)
Adjusted for acute coronary syndrome and percent area stenosis on angiographybeen previously published. Similarly, TSP polymorphisms
have been linked to the risk of MI [40] and the presence
of coronary atherosclerosis [41], but to our knowledge, the
association of circulating concentrations with plaque bur-
den or collateralization has not been previously reported.
Lastly, despite experimental models convincingly linking
ANG with myocardial vascular supply [42], we are aware
of only a single, small study investigating the associ-
ation between ANG and human coronary artery disease
in which ANG concentration was not associated with
atherosclerosis (as assessed by maximal percent sten-
osis) or with collateral supply [43].
Our study extends prior reports by assessing associa-
tions of END, ENG, TSP, and ANG with both plaque
burden and collateral supply in a single cohort. As noted
above, the use of QCA techniques and a fully quantita-
tive measurement of plaque burden represent other
unique features of our study. The larger sample size of
our study compared to most prior analyses of theseoncentration with collateral formation
P value Adjusted odds ratio (95 % CI) P value
0.44 0.91 (0.65, 1.28) 0.61
0.56 1.04 (0.73, 1.50) 0.81
0.59 0.97 (0.93, 1.02) 0.21
0.39 0.76 (0.46, 1.26) 0.28
0.88 1.05 (0.88, 1.25) 0.60
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but we did not identify any significant associations in ei-
ther crude or adjusted models. Our findings suggest that
associations of circulating END, ENG, TSP, and ANG
with cardiovascular mortality are unlikely to be mediated
via direct effects on coronary plaque formation or by
inhibition of collateral formation. Whether local concen-
trations, myocardial tissue expression, or intra-plaque ex-
pression plays a more important role or whether these
factors could impact plaque vulnerability is unknown. Add-
itional studies in larger cohorts with the ability to analyze
tissue and pericardial expression are clearly warranted.
Our findings should be interpreted within the context
of our study design. Power to rule out small differences
in concentration between groups was limited. Our findings
did not particularly suggest trends across groups in mea-
sured concentration although there were non-significant
differences across groups in END concentration. Larger
studies are needed to definitively rule out differences. The
sample sizes used allowed us to correct for the most im-
portant factors in multi-variable models but did not permit
simultaneous adjustment for all potential confounder-
s—particularly in the analysis of collaterals, where the over-
all number of collaterals was low. Lastly, our subjects came
from a single center, and our results may not be fully
generalizable to populations with different genetic back-
grounds or indications for angiography. Lastly, we were
unable to measure tissue concentrations or localized blood
concentrations for the measured factors. Thus, larger,
multi-center studies with the ability to measure tissue or
local factor concentrations should be considered.
Conclusions
In conclusion, we used QCA to analyze associations of a
broad panel of related NO and angiogenesis inhibitors
with plaque burden and collateral formation using quanti-
tative coronary angiography. We did not find any signifi-
cant associations between the severity of atherosclerosis or
collateral formation and the circulating concentrations of
ADMA, END, ENG, ANG, or TSP. Our findings suggest
that the circulating concentration of these factors may not
be important determinants underlying the development of
atherosclerosis or the formation of coronary collaterals.
Further studies to confirm our findings and to investigate
the impact of tissue or local concentrations of angiogen-
esis and NO inhibitors on coronary atherosclerosis and
plaque vulnerability should be considered.
Methods
Ethical approvals
This study was approved by the Partners Human Re-
search Committee and institutional review board of the
Beth Israel Deaconess Medical Center (both in Boston,
Massachusetts). All research was in compliance withrelevant regulation and the Helsinki declaration. Written
informed consent for participation, phlebotomy, and
analysis of biologic samples and data was obtained from
all participating subjects.
Study population
Individuals between 18–80 years of age were recruited
from the cardiac catheterization suite at a single center.
Subjects with a history of coronary bypass surgery or
undergoing emergency angioplasty in the setting of
acute myocardial infarction (MI) were excluded as were
individuals with acute kidney injury, those receiving
anti-angiogenic or immunosuppressive medications, and
individuals with a history of thoracic radiation or cancer.
Subjects underwent a brief interview and physical exam,
and additional clinical data were extracted by chart re-
view. Serum and plasma were collected before angiog-
raphy, centrifuged within 20 min at 1000×g, and stored
at −80 °C. Serum creatinine and blood counts were mea-
sured on the day of the procedure in the clinical labora-
tory, and cholesterol measurements within 6 months prior
to enrollment were recorded. Glomerular filtration rate
(eGFR) was calculated using the pre-procedure creatinine
and the modified MDRD equation [44].
Measurement of circulating factors
Endoglin (ENG), serum END, and ANG were measured
using Quantikine® ELISA (R&D Systems) with intra- and
inter-assay coefficient of variations (CVs) <7.0 and <13.2 %,
respectively. A Luminex assay (R&D Systems) was used to
measure TSP with CVs <8.7 and 16.4 %, respectively.
Plasma ADMA was measured by HPLC according to the
method of Teerlink [45] (intra and inter-assay CV <3.5 %).
Angiographic analysis
All coronary angiograms were analyzed by a single reader
using standard QCA software (Cardiology Medis System,
version 5.1, Nuenen, The Netherlands). Foreshortening
and measurement variability were minimized by utilizing a
standard sequence of angiographic views [46] and by cali-
brating sizes against catheter dimensions [47]. Percent
stenosis was recorded only when ≥20 %—the lower limit of
reliable discrimination. Arteries with diameters <1.75 mm
were not assessed because these segments were considered
too small for accurate QCA.
Two-dimensional plaque area was quantitatively mea-
sured within each coronary artery segment (Fig. 2). The
differences in the total length and evaluable portion of in-
dividual coronary arteries were standardized by using the
percent area stenosis—defined as the two-dimensional
area occupied by luminal plaque divided by the total lu-
minal area of all evaluated coronary segments—as the pri-
mary outcome. The Gensini score [48] was assessed in a
sensitivity analysis.
Fig. 2 Images from QCA of coronary angiogram before (a) and after (b) digital processing. a Thick arrow shows typical area without significant
luminal irregularities. Thin arrows point to luminal narrowing and irregularity. b Post-processing images demonstrating the vessel wall outlined in
black and areas with luminal irregularity traced in white
Charytan et al. Fibrogenesis & Tissue Repair  (2015) 8:13 Page 8 of 10Coronary collateral formation was assessed using the
Rentrop classification [49]—a four-point, semi-quantitative
system in which scores are scaled from 0 to 3: 0 (no
visible collaterals), 1 (side branch filling via collateral
channels), 2 (partial filling of the epicardial arterial seg-
ment via collaterals), and 3 (complete filling through
dilated collaterals).Statistical analysis
Data are presented according to their distribution as
mean ± standard deviation (SD), n (%), or median (IQR).
In unadjusted analyses, differences were compared using
ANOVA or Kruskal-Wallis tests for continuous data and
Chi-square tests for count data. Adjusted outcomes were
assessed using multi-variable linear regression (percent
area stenosis, Gensini score) or logistic regression (col-
lateral formation) with logarithmic transformation of
outcome variables as needed to preserve normality. In a
secondary analysis using collateral supply to each indi-
vidual coronary artery as the unit of analysis, we used
robust standard errors and clustering by individual to
account for the correlation in the propensity to form
collaterals between multiple arteries (left, right, and cir-
cumflex coronary arteries) within a given individual.
Model fit was tested graphically, by inspecting residuals
and by testing model specification. The analyses were
performed in STATA 13.0 (STATA Corp.) with P < 0.05
considered significant.Abbreviations
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